Please provide your email address to receive an email when new articles are posted on . “The importance of our results is that we can have better efficacy while potentially enhancing adherence by ...

The introduction of Rocklatan, a once-daily, fixed-dose combination of the rho kinase inhibitor netarsudil and the prostaglandin analogue latanoprost, has broadened the spectrum of medical management ...

Glaucoma is one of the three leading causes of blindness in Germany and worldwide. This neurodegenerative disease progressively damages the retinal nerve fibres, leading to irreversible vision loss.

Alcon, the global leader in eye care and a division of Novartis, has received US Food and Drug Administration (FDA) approval for Simbrinza suspension, indicated for the reduction of elevated ...

Open angle glaucoma is the most common type of glaucoma. The high eye pressure damages the optic nerve, which connects the eye to the brain, resulting in decrease in vision. It is important to treat ...

St. Louis, June 13, 2002 -- A study led by investigators at Washington University School of Medicine in St. Louis has found that drops that lower eye pressure can delay the onset of glaucoma. The eye ...

Researchers have discovered that eye drops used to treat elevated pressure inside the eye can be effective in delaying the onset of glaucoma. These results mean that treating people at higher risk for ...

A broad review of therapeutic classes approved for the management of glaucoma and how they may be sequenced. Neil Minkoff, MD: And just to help make sure that we’re all at least on a level playing ...

Expert perspectives on the factors that inform therapy selection when managing patients with glaucoma. Neil Minkoff, MD: One of the things that I’m trying to get my arms around here is that we’ve been ...